glp-1 gip therapy alternatives 2025 What is the pipeline for future medications for obesity? GLP-1 Analogues Market Size to

As ITCA 650 contributed minimally to the pooled estimate, its potential bias did not materially affect the overall assessment

CD4+ CD25+ Tregs are a subpopulation of T cells that are effective in reducing inflammation (44, 45)

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a doubleblind, randomised placebocontrolled trial

Studies that include patients who are considered at-risk (i.e., diabetics, cardiac, elderly, etc.) and are currently taking GLP-1 RAs should also be performed as these patients may have compounding risk during the perioperative period which may make them more susceptible to complications related to GLP-1 use (Santos et al

Agents in this class are approved for treatment of type 2 diabetes and reduction of cardiovascular disease, as well as weight management